{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-060031","form_type":"8-K","ticker":"OLMA","cik":"0001750284","company_name":"Olema Pharmaceuticals, Inc.","filed_at":"2024-05-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.885696+00:00","generated_at":"2026-06-01T23:23:21.398222+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Olema reports interim Phase 1b/2 data: palazestrant + ribociclib shows 85% CBR in ER+/HER2- mBC","bullets":["Combination well tolerated in 50 patients; no new safety signals and no clinically meaningful drug-drug interaction.","Clinical benefit rate of 85% (11/13) overall; 83% in ESR1-mutant, 86% in wild-type, 83% in prior CDK4/6i patients.","Partial responses observed in 5 of 23 evaluable patients (2 confirmed, 3 unconfirmed); 66% remain on treatment.","Study fully enrolled at 60 patients; data support continued development for first-line ER+/HER2- advanced breast cancer."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-060031","json":"https://secwatch.observer/filing/0000950170-24-060031.json","markdown":"https://secwatch.observer/filing/0000950170-24-060031.md","text":"https://secwatch.observer/filing/0000950170-24-060031.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1750284/000095017024060031/0000950170-24-060031-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1750284/000095017024060031/olma-20240515.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T23:23:21.398222+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}